2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Infections
8
Neoplasms
7
Neutropenia
6
Lymphoma
6
Prostatic Neoplasms
5
Leukemia
5
Neoplasms, Plasma Cell
4
Lymphoma, Non-Hodgkin
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Febrile Neutropenia
3
Waldenstrom Macroglobulinemia
2
Urinary Tract Infections
2
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Pancreatic Cyst
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Intraocular Lymphoma
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Interventions
Radiosurgery
3
Filgrastim
2
pegfilgrastim
1
Paclitaxel
1
DAT protocol 1
1
Ciprofloxacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Early Stage Breast Cancer
×
Ciprofloxacin
×
Clear all
NCT02816112
2020-05-27
REaCT-TC2
Ottawa Hospital Research Institute
Phase 4
Completed
458 enrolled